Atherosclerotic risk assessment of androgen therapy in aging men

Textbook of Men's Health and Aging: 2nd Edition

Volumn , Issue , 2007, Pages 465-471

  Crook, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51649116178     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (31)

1. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J 1987; 114: 1467-503.
2. Kennedy R. http://www.medical-library.net/sites/framer.html?/sites/testerone therapy.html.
3. Lopez AD, Murray CCJL. The global burden of disease: 1990-2020. Nature Med 1998; 4: 1241-3.
4. Braunwald E. Shattuck Lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N Engl J Med 1997; 337: 1360-9.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-25.
6. Barrett Connor EL. Testosterone and risk factors for cardiovascular disease in men. Diabetes Metabol (Paris) 1995; 21: 156-61.
7. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125: 1-13.
8. English KM, Steeds R, Jones TH, Channer KS. Testosterone and coronary heart disease: is there a link? Q J Med 1997; 90: 787-91.
9. Crook D. Androgen therapy in the aging male: assessing the effect on heart disease. Aging Male 1999; 2: 1-6.
10. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998; 41: 1-15.
11. Rockhold RW. Cardiovascular toxicity of anabolic steroids. Ann Rev Pharmacol Toxicol 1993; 33: 497-520.
12. Parssinen M, Kujala U, Vartiainen E et al. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000; 21: 225-7.
13. Mittleman MA, Maclure M, Tofler GH et al. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993; 329: 1677-83.
14. Sader MA, Griffiths KA, McCredie RJ et al. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. JACC 2001; 37: 224-30.
15. Hanke H, Lenz C, Hess B, et al. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001; 103: 1382-5.
16. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 1995; 15: 562-70.
17. Obasanjo IO, Clarkson TB, Weaver DS. Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Metabolism 1996; 45: 463-8.
18. Von Eckardstein A. Androgens, cardiovascular risk factors and atherosclerosis. In: Nieschlag E, Behre HM, eds. Testosterone. Berlin: Springer, 1998: 229-58.
19. Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormone binding globulin, lipoproteins and vascular disease risk. J Cardiovasc Risk 1997; 4: 363-6.
20. Ferenchick G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci 1992; 303: 78-82.
21. Ferenchick GS, Hirowaka S, Mammen EF, Schwartz KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49: 282-8.
22. Crook D, Von Eckardstein A, Dieplinger H et al. Tibolone lowers HDL concentrations but does not impair cholesterol efflux from cells. Maturitas 2000; 35: 7-8.
23. Van Kesteren PJ, Kooistra T, Lansink M et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemostasis 1998; 79: 1029-33.
24. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest 1999; 22(5 Suppl): 110-6.
25. Phillips GB, Pinkernell BH, Jing T-Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701-6.
26. English KM, Mandour O, Steeds RP et al. Men with coronary heart disease have lower levels of androgens than men with normal coronary androgens. Eur Heart J 2000; 21: 890-4.
27. Adamkiewicz M, Zgliczynski S, Slowinska-Srzednicka J et al. Androgens (testosterone and dehydroepiandros- terone-sulfate) and coronary arteriosclerosis in men. Presented at III Internationales Grazer AndrologieSymposion. Graz 2000; 2: 31.
28. Phillips GB, Pinkernell BH, Jing T-Y. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 1997; 17: 695-701.
29. Crews JK, Kahil RA. Antagonistic effects of 17 B- estradiol, progesterone and testosterone on calcium entry mechanisms of coronary vasoconstriction. Atheroscler Thromb Vasc Biol 1999; 19: 1034-40.
30. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 1999; 99: 2317-22.
31. English KM, Jones RD, Jones TH et al. Aging reduces the responsiveness of coronary arteries from male Wister rats to the vasodilatory action of testosterone. Clin Sci 2000; 99: 77-82.